Skip to Content

Dear Customer:

The current international situation is complex and volatile, and uncertain tariff policies may potentially impact our product prices. Given these uncertainties, we value your understanding regarding order-related matters.

If you decide to place an order during this period, we reserve the right to adjust the price based on the evolving situation. We understand that market changes may cause inconvenience. We will negotiate with you if there’s a significant price fluctuation due to tariff policy changes before the order’s actual delivery, and in such cases we may adjust or cancel the order as necessary.

We are planning system maintenance between Friday, Apr 18 at 9:00 PM CDT and Saturday, Apr 19 at 9:00 AM CDT. This will impact both web and offline transactions, including online orders, quotes, price and availability checks, and order status inquiries. We apologize for any inconvenience.

For important updates on recent policy changes, please click here for more details.

Merck
CN
  • Enhanced CRAd activity using enhancer motifs driven by a nucleosome positioning sequence.

Enhanced CRAd activity using enhancer motifs driven by a nucleosome positioning sequence.

Molecular therapy : the journal of the American Society of Gene Therapy (2013-05-29)
Soraya Bravo, Felipe Núñez, Fernando Cruzat, Eduardo G Cafferata, Giancarlo V De Ferrari, Martín Montecino, Osvaldo L Podhajcer
ABSTRACT

Cancer development involves changes driven by the epigenetic machinery, including nucleosome positioning. Recently, the concept that adenoviral replication may be driven by tumor specific promoters (TSPs) gained support, and several conditionally replicative adenoviruses (CRAd) exhibited therapeutic efficacy in clinical trials. Here, we show for the first time that placing a nucleosome positioning sequence (NPS) upstream of a TSP combined with Wnt-responsive motifs (pART enhancer) enhanced the TSP transcriptional activity and increased the lytic activity of a CRAd. pART enhanced the transcriptional activity of the gastrointestinal cancer (GIC)-specific REG1A promoter (REG1A-pr); moreover, pART also increased the in vitro lytic activity of a CRAd whose replication was driven by REG1A-Pr. The pART enhancer effect in vitro and in vivo was strictly dependent on the presence of the NPS. Indeed, deletion of the NPS was strongly deleterious for the in vivo antitumor efficacy of the CRAd on orthotopically established pancreatic xenografts. pART also enhanced the specific activity of other heterologous promoters; moreover, the NPS was also able to enhance the responsiveness of hypoxia- and NFκB-response elements. We conclude that NPS could be useful for gene therapy approaches in cancer as well as other diseases.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Monoclonal Anti-Actin antibody produced in mouse, clone AC-40, ascites fluid
Sign Into View Organizational & Contract Pricing
SKUPack SizeAvailabilityPriceQuantity
25 g
Available to ship on April 18, 2025
Details...
CN¥933.32
100 g
Available to ship on April 18, 2025
Details...
CN¥1,718.03
Sigma-Aldrich
Anti-Histone H3 Antibody, CT, pan, clone A3S, rabbit monoclonal, clone A3S, Upstate®, from rabbit
Sign Into View Organizational & Contract Pricing
SKUPack SizeAvailabilityPriceQuantity
25 g
Available to ship on April 18, 2025
Details...
CN¥933.32
100 g
Available to ship on April 18, 2025
Details...
CN¥1,718.03